AlphaMaven AlphaMaven

venBio Closes $394 Million Life Sciences Venture Capital Fund

Reported by Business Wire
Apr 3, 2020· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • venBio Partners LLC closed venBio Global Strategic Fund III at approximately $394 million in capital commitments, exceeding its target in an oversubscribed fundraise, according to a Business Wire announcement dated April 3, 2020.
  • • The fund draws from a broad institutional base including pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds, alongside existing investors.
  • • The firm will continue investing primarily in therapeutics developing biopharmaceuticals for unmet medical needs, typically leading or co-leading rounds, with a 3- to 5-year investment horizon.
  • • venBio, founded in 2011, has raised nearly $1 billion in cumulative capital commitments and has invested in 29 companies, three of which have developed approved drugs now on the market.
  • • Richard Gaster, M.D., Ph.D., was promoted to Partner in conjunction with the new fund.
Summary
venBio Partners LLC announced the final close of venBio Global Strategic Fund III ("venBio Fund III"), its third life sciences venture capital fund, with approximately $394 million in capital commitments. The company said the raise exceeded its target and was oversubscribed. Capital came from existing investors and new ones, including pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds.

The fund will be led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., and Aaron Royston, M.D. It will continue to focus primarily on therapeutics companies developing biopharmaceuticals for unmet medical needs. According to the firm, the venBio team typically leads or co-leads its investments and takes an active role in each portfolio company. Dr. Goodman said the firm's investment thesis, regardless of company stage, remains to seek opportunities with a 3- to 5-year time horizon, and that the strategy is to "turn great science into impactful medicine." Dr. Royston noted that three companies the firm helped build have developed approved drugs currently on the market.

venBio was established in 2011 and has raised nearly $1 billion in capital commitments since inception. It has invested in 29 companies, including venBio-founded Labrys Biologics (acquired by Teva), Aragon Pharmaceuticals (acquired by Johnson & Johnson) and Seragon Pharmaceuticals (acquired by Roche). Other portfolio companies include Aurinia Pharmaceuticals (NASDAQ: AUPH), Apellis Pharmaceuticals (NASDAQ: APLS), Turning Point Therapeutics (NASDAQ: TPTX), Precision Biosciences (NASDAQ: DTIL) and Akero Therapeutics (NASDAQ: AKRO).

In conjunction with the fund close, venBio promoted Richard Gaster, M.D., Ph.D., to Partner. Dr. Gaster was previously head of translational medicine at Pliant Therapeutics and a Senior Associate at Third Rock Ventures.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Business Wire venBio Closes $394 Million Life Sciences Venture Capital Fund